Cellectis (NASDAQ:CLLS) Shares Pass Above Fifty Day Moving Average - Here's WhyMarket Beat·Aug 19 at 01:40 AMCLLS-1.87%UBS+0.17%
10:31 ETCAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Grow Significantly at a CAGR of 6.8% During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Pipeline | DelveInsightprnewswire·Aug 12 at 09:31 AMCLLS-1.87%AUTL-2.03%
Cellectis publishes corporate presentation on allogeneic CAR-T pipeline, TALEN gene-editing platformPUBT·Aug 7 at 05:16 AMCLLS-1.87%
Cellectis expects interim readout in Q4 2026 from pivotal BALLI-01 trial of lasme-cel in relapsed/refractory B-cell ALLPUBT·Aug 6 at 04:58 PMCLLS-1.87%
Cellectis H1 FY26 net loss narrows 5.49% to USD 39.58 million; revenue drops 52.19% to USD 14.45 millionPUBT·Aug 6 at 03:33 PMCLLS-1.87%
Cellectis reports 100,701,207 issued shares, 105,554,794 voting rights as of July 31, 2026PUBT·Aug 5 at 03:38 PMCLLS-1.87%
Cellectis to Report Second Quarter Financial Results on August 6, 2026Unusual Whales·Jul 30 at 03:32 PMCLLS-1.87%
Qube Research & Technologies discloses net short position in Cellectis sharesPUBT·Jul 29 at 08:58 AMCLLS-1.87%
Monthly information on share capital and company voting rights | CLLS Stock NewsStockTitan·Jul 2 at 07:30 AMCLLS-1.87%
Cellectis amends 6-K to correct shareholder meeting voting results tablePUBT·Jun 26 at 03:31 PMCLLS-1.87%
Cellectis held shareholder meeting; resolutions 1-29 adopted, 30 rejectedPUBT·Jun 25 at 03:30 PMCLLS-1.87%
Ferretti Leads The Charge In European Penny Stock OpportunitiesSimplywall·Jun 12 at 12:23 AMCLLS-1.87%
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress | CLLS Stock NewsStockTitan·Jun 10 at 05:40 PMCLLS-1.87%
